Format

Send to

Choose Destination
Hum Vaccin Immunother. 2016 May 3;12(5):1102-16. doi: 10.1080/21645515.2015.1122146. Epub 2015 Dec 2.

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

Author information

1
a Scientific Institute of Public Health (WIV-ISP), Biosafety and Biotechnology Unit , Brussels , Belgium.
2
b Division of Medical Oncology , Mayo Clinic , Rochester , MN , USA.
3
c Institut Pasteur, Viral Genomics and Vaccination Unit, CNRS UMR 3569 , Paris , France.

Abstract

Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it attractive candidate vector to prevent infectious diseases. Attenuated MV have acquired the ability to use the complement regulator CD46 as a major receptor to mediate virus entry and intercellular fusion. Therefore, attenuated MV strains preferentially infect and destroy a wide variety of cancer cells making them also attractive oncolytic vectors. The use of recombinant MV vector has to comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The present article highlights the main characteristics of MV and recombinant MV vectors used for vaccination and virotherapy and discusses these features from a biosafety point of view.

KEYWORDS:

MV Edmonston strains; biosafety; measles virus (MV); vaccination; viral vectors; virotherapy

PMID:
26631840
PMCID:
PMC4963060
DOI:
10.1080/21645515.2015.1122146
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center